Business
GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics
--Data demonstrates that rapid genomic testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days --Despite broad
About this update from Genedx Holdings Corp.
[{"type":"text","content":"\n--Data demonstrates that rapid genomic testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days\n\n\n--Despite broad utilization in the study, rapid genomic sequencing in non-critical care inpatients yielded a diagnostic rate over 42%, comparable to critical care settings\n\n\n--Study supports broader adoption of rapid genomic testing in the non-critical care inpatient setting to improve pediatric patient outcomes and lower healthcare costs\n\n\n GAITHERSBURG, Md.--(BUSINESS WIRE)--\nGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in partnership with the clinical genetics team at Seattle Children’s supporting the application of rapid exome sequencing (rES) and rapid genome sequencing (rGS) as a first-tier test for non-critical pediatric inpatients. The study assessed the impact of using rES/rGS as a first-tier test for children receiving genetic consults in non-critical care settings. The researchers examined diagnostic rates before and after a new policy allowing rES/rGS as a first-tier test was implemented. An analysis published in The Journal of Pediatrics showed that rapid genome testing dropped the average time to a precise genetic diagnosis from almost ten months to less than two weeks.\n\n\n“Pediatric inpatients often remain undiagnosed and stuck in limbo without answers or treatment as their conditions worsen and costs rise for way too long,” said Mike Bamshad, MD, FACMG, Professor of Pediatrics at the University of Washington School of Medicine and Division Chief of Genetic Medicine at Seattle Children’s. “The study demonstrated how a policy change allowing for rapid genomic testing as a first-tier test significantly reduced the time to diagnosis in non-critical care pediatric wards, enabling patients to receive timely treatments and potential better outcomes.”\n\n\nImplementation of the SeqFirst approach in the clinical setting led to significant reductions in the time to a genetic diagnosis, with the average time dropping from 289 to 13 days following the policy change that enabled rES/rGS to be ordered as a first-tier test in non-critical care pediatric wards. Despite an increase in utilization of rES/rGS, the diagnostic yield remained high, exceeding 40 percent, c...